TABLET FORMULATION CONTAINING HAWTHORN (CRATAEGUS) EXTRACT

Abstract

The present invention relates to a tablet formulation containing extracts of various hawthorn (Crataegus) species. A method for preparing the tablet formulation is also provided within the scope of the invention. The hawthorn extract included in the formulation of the present invention is obtained from the hawthorn species Crataegus pentagyna, Crataegus szovitsii, Crataegus aronia, Crataegus curvisepala and Crataegus monogyna.

Claims

1. Crataegus pentagyna, Crataegus szovitsii, Crataegus aronia, Crataegus curvisepala and A tablet containing an extract of Crataegus monogyna species and at least one excipient. formulation.

2. The tablet formulation submitted pursuant to Claim 1 has the characteristic of containing at least one excipient. The components include highly dispersed silicon dioxide (Aerosil), magnesium stearate, Neucilin US2, fluorite, avicel, klucel LF, klucel EXF, polyplasdon XL, lactose monohydrate, sodium carboxymethyl starch (type A), macrogol 6000, talcum, titanium dioxide, microcrystalline cellulose, povidone K 25, sodium carmellose, povidone K 90 and combinations thereof It is the selection of a group that includes.

3. The tablet formulation submitted pursuant to Claim 1 or 2 has at least one of the following characteristics: The excipients are fluoride, avicel, and magnesium stearate.

4. The tablet formulation submitted according to Claim 1 is characterized by the fact that the extract in question is in tablet form. It should be present in the formulation at a rate of 20% to 40% by weight.

5. The tablet formulation submitted according to claim 1 or 4 is characterized by the extract in question. The amount should be between 100 and 200 mg.

6. The tablet formulation submitted pursuant to Claim 5 is characterized by the fact that the amount of the extract in question is 115 It is mg.

7. The tablet formulation submitted pursuant to Claim 3 has the characteristic contained in said formulation. The ratio of the field extract to fluoride is between 1:1 and 1:0.

5.

8. This is the tablet formulation presented according to Claim 3, and its characteristic feature is that of avicelin tablet formulation. It should be between 40% and 55% by weight.

9. This is a tablet formulation submitted according to Claim 3, characterized by its magnesium stearate content in tablets. It is present in the formulation at a rate of 0.1% to 1% by weight. 35 10. This is a method for preparing the tablet formulation submitted according to Claim 1, Its feature involves the following steps: - Crataegus pentagyna, Crataegus szovitsii, Crataegus aronia, Crataegus curvisepala and Collecting, drying, and powdering Crataegus monogyna species. 12 - The resulting powder is subjected to ultrasonic extraction using a solvent, - obtaining the extract by subjecting the solution to the lyophilization process, - combining the extract with at least one auxiliary component, - pressing the resulting mixture into tablet form, and - obtaining the final tablet formulation.

11. The method presented in accordance with claim 10 is characterized by having at least one auxiliary component. the aggregation step involves combining the extract with fluoride, Avicel, and magnesium stearate. It is accomplished by bringing it about.

12. For use in the prevention and / or treatment of cardiovascular diseases. Tablet formulation presented according to claim 1. 13 Specifications TABLET FORMULATION CONTAINING HAWTHORN (CRATAEGUS) EXTRACT Field of Invention The present invention relates to a tablet formulation containing hawthorn (Crataegus) extract. The invention... A method for preparing the tablet formulation is also included in the invention. is provided. State of the Art The fruits, flowers, and leaves of hawthorn species (Crataegus species) are used for medicinal purposes in various geographical regions. It is used because of its effects. Especially in European countries, the USA and China, which have aging populations. In various countries, hawthorn is used as an antioxidant and in age-related cardiovascular diseases. The use of various species is well known. In addition to this widespread use of Crataegus species, various being registered in pharmacopoeias, animal studies regarding physiological activities and mechanisms of action numerous studies have been conducted with volunteers, and there are no known toxicities or side effects. These are the main reasons why they were chosen as research topics. Some of the most important plants in treatment and preventive medicine are used in cardiovascular diseases. These are the uses. Different types of hawthorn are used in the treatment of heart diseases in various geographical regions. Its use is known; for example, C. pinnatifida in China, C. pubesens in Mexico, C. in Japan. cuneata, C. laevigata and C. monogyna in Europe, C. oxycantha and C. aronica in the Middle East, C. Phaenopyrum is used in America and C. ambigua is used in Russia. Studies have shown that hawthorn species have a rich content of secondary metabolites. It has been shown that hawthorn fruits contain 0.1-1% flavonoids, 0.5-1.4% triterpene acids, and 1-2% It contains oligomeric proanthocyanidins (OPCs) and 2-6% organic acids; leaves and flowers The mixture was found to contain 1-2% flavonoids and 1-3% OPCs. Patent document CN 106938047 A relates to a coated pepsin tablet. A coated pepsin tablet consists of a tablet core and a coating film. The aforementioned tablet core, 5% to 10% clove leaf extract, 5% to 10% hawthorn extract by weight and It contains 0.01% to 0.02% pepsin. These tablets help eliminate symptoms of indigestion. It is presented with the aim of having it removed. 35 1 Patent document number US 5910308 A, Gynostemma pentaphyllum extract, Crataegus pinnatifida herbal extract containing hawthorn leaves or berries and Camellia sinensis extract (green tea) It relates to a composition based on green tea. Also within the scope of the document, hawthorn fruits are mentioned in relation to green tea. extracts from each of the leaves of Gynostemma pentaphyllum a method for preparing a plant extract-based composition that involves processing is provided. In light of the information presented above, there are ways to benefit human health and treat various diseases. Studies involving hawthorn extracts were conducted under the current state of the art. It is observed that, however, an extract containing various hawthorn species together is used in tablet formulation. No studies have been found on this subject. Therefore, blood pressure regulation, lowering cholesterol levels, preventing and / or treating cardiovascular diseases and various hawthorn varieties presented for use in the treatment of heart failure. The need for tablet formulations containing extracts of these species still exists in the relevant technical field. This continues. In line with this need, within the scope of the present invention, Crataegus pentagyna, Crataegus szovitsii, Crataegus aronia, Crataegus curvisepala and Crataegus monogyna species A tablet formulation containing the extract and at least one auxiliary component is presented. The invention... Crataegus pentagyna, Crataegus szovitsii, and Crataegus aronia are included in the tablet formulation. Synergistic effect of Crataegus curvisepala and Crataegus monogyna species and high metabolite This quantity makes the formulation of the invention advantageous. Furthermore, the existing inventors... a tablet formulation containing species extracts, in terms of bioaccessibility, the technique They have shown that it has had an impact that goes beyond its known status. Brief Description of the Invention The present invention, in one aspect, relates to Crataegus pentagyna, Crataegus szovitsii, Crataegus aronia, Crataegus extract of the species Crataegus curvisepala and Crataegus monogyna and containing at least one auxiliary component It offers a tablet formulation. The tablet formulation of the present invention shall preferably use highly dispersed silicon dioxide (aerosil), magnesium stearate, neucillin US2, fluoride, avicel, klucel LF, klucel EXF, polyplasdon XL, lactose monohydrate, sodium carboxymethyl starch (type A), macrogol 6000, talcum, titanium dioxide, microcrystalline cellulose, povidone K 25, sodium carmellose, povidone K 90 and their It contains at least one auxiliary component selected from a group that includes combinations of these components.

35. In a preferred configuration of the present invention, at least one of the formulations of the invention The excipients are fluoride, avicel, and magnesium stearate. 2 In the preferred formulations of the invention, the extract in question constitutes 20% by weight in the tablet formulation. It ranges from 100 to 200 mg of the extract. It is within this range. More preferably, the amount of hawthorn extract is 115 mg. The Avicel tablet in question... It is preferably present in the formulation in the range of 40% to 55% by weight. Magnesium stearate is preferably present in tablet formulations at a concentration of 0.1% to 1% by weight. It is located. In the preferred configurations of the invention, the ratio of the extract to fluoride in the formulation of the invention is between 1:1 and... The ratio is 1:0.

5. In another aspect, the invention relates to the preparation of the tablet formulation according to the invention. It provides a method which includes the following steps: - Crataegus pentagyna, Crataegus szovitsii, Crataegus aronia, Crataegus curvisepala and Collecting, drying, and powdering Crataegus monogyna species. - The resulting powder is subjected to ultrasonic extraction using a solvent, - obtaining the extract by subjecting the solution to the lyophilization process, - combining the extract with at least one auxiliary component, - pressing the resulting mixture into tablet form, and - obtaining the final tablet formulation. The method described in the present invention should preferably be combined with at least one of the aforementioned auxiliary components. The next step is to combine the extract with fluoride, Avicel, and magnesium stearate. Another aspect of the invention is its potential in the prevention and / or treatment of cardiovascular diseases. A tablet formulation based on the invention is presented for use. Detailed Description of the Invention This detailed description of the invention's tablet formulation is provided for better understanding and without any It is described in detail in a way that will not create a limiting effect. This tablet formulation is used to lower blood pressure and blood cholesterol levels, and for heart health. in the prevention and treatment of diseases, in reducing the signs of skin aging, and In addition to being effective in facilitating digestion, it also has anti-inflammatory properties. C. Extracts of 35 pentagyna, C. szovitsii, C. aronia, C. curvisepala and C. monogyna species and at least one Species C. pentagyna Waldst. & containing an auxiliary component in the tablet formulation of the invention. 3 Scarce. ex Willd., C. szovitsii Pojark, C. aronia (L.) Bosch. ex DC., C. curvisepala Lindman and C. monogyna Also known by the names Jacq. Four of these are endemic to Türkiye according to its flora (C. davisii Browicz, C. tanacetifolia (Lam.) Pers., C. x There are 17 hawthorn species (21 taxa) (bornmuelleri Zabel, C. dikmensis Pojark.) (Sect. Pentagynae Schneider 2 species; Sect. Azaroli Loud. 6 species; Sect. Crataegus 9 species). In addition, C. aronia (L.) Bosc. The species is divided into 3 varieties. Two of these (C. aronia var. dentata Browicz, C. aronia var. minuta) Browicz is an endemic species. Other comprehensive studies have identified 6 hybrid species (Nothospecies). and 4 new species (C. tursicus Dönmez, C. yaltırıkii Dönmez, C. christensenii Dönmez, C. peshmenii (As described by Dönmez), it has been revealed that there are a total of 27 species in Türkiye. Among the many substances isolated from hawthorn species are flavonoids and OPCs, which are bioactive compounds. These are two major groups. The pharmaceutical activity of Crataegus leaves, flowers and fruits is due to OPCs and glucose-bound derivatives of flavonoids (flavonol-O-glucosides, vitexin 2''-C-rhamnoside, acetyl It is believed to originate from vitexin-2''-O-rhamnoside. The flavonoids found in Crataegus species are mainly flavonol-O-glucosides and flavon-C-glucosides. It has numerous derivatives, including those listed above. There are approximately 50 flavonoids in C. pinnatifida species alone. It has been determined that there are a total of 158 secondary metabolites. Flavones (for example) apigenin, luteonin, orientin, vitexin, vitexin rhamnoside, isovitexin, hyperoside), flavonols (e.g., kaempferol, quercetin, bioquercetin, rutin, pinnatifidin), flavanones, flavanol polymers There are also many other compounds like these. Crataegus (especially C. pinnatifida, C. 750) is found in Europe and North America as well as in China. Products (oxyacantha and C. laevigata) have therapeutic effects as well as being non-toxic or having low toxicity. They hold an important place due to their toxicity. Especially in age-related diseases (for example cardiovascular diseases, arteriosclerosis, arthritis, hypertension), nervous system disorders (for example, migraine) and upper respiratory tract infections, hypercholesterol, cellulite, obesity and products derived from hawthorn species in the prevention and treatment of menopausal disorders. It is recommended. The inventors conducted their studies on specimens collected from species in Türkiye. As a result, among the hawthorn species, especially Crataegus pentagyna, Crataegus szovitsii, and Crataegus Aronia, Crataegus curvisepala and Crataegus monogyna species have high metabolite levels. It has come to the forefront for 35 reasons. The inventors, within a formulation, used the aforementioned hawthorn species. that they create a synergistic effect in combination and that the individual therapeutic effects of the species are similar. They noticed that it increased thanks to the combination. Therefore, the hawthorn extract in the invention 4 while being prepared, especially Crataegus pentagyna, Crataegus szovitsii, Crataegus aronia, Crataegus The species curvisepala and Crataegus monogyna were preferred. The inventors, based on the dosage values ​​recommended by ESCOP, have included the types of invention related to this invention. Eden offers a tablet formulation of hawthorn dry extract. Relevant guidelines and monographs. hawthorn berries, whose quality control parameters have been tested and standardized accordingly. Formulation studies of the extract and tablet dosage form have been carried out. In the preferred configurations of the invention, at least one auxiliary component of the invention shall preferably be high-performance. dispersed silicon dioxide (Aerosil), magnesium stearate, Neucilin US2, fluoride, Avicel, Klucel LF, klucel EXF, polyplasdon XL, lactose monohydrate, sodium carboxymethyl starch (type A), macrogol 6000, talcum, titanium dioxide, microcrystalline cellulose, povidone K 25, sodium carmellose, povidone It is selected from a group that includes K 90 and combinations thereof. Standardized hawthorn. Thanks to the formulations developed primarily in a laboratory environment with its dry extract, the invention The relevant auxiliary components suitable for their purposes have been identified. In the resulting hawthorn extract; Analysis of parameters such as friability (crumbling), dissolution, disintegration, and content uniformity. The tablet formulation of the present invention is produced using the necessary appropriate equipment to achieve the desired results. It has been proven to possess these properties. One aim of the present invention is to achieve the moisture content / balance of the formulation. The aim is to prevent the extract from becoming soft and sticky and from clumping. In line with this, in a preferred configuration of the present invention; auxiliary elements together with hawthorn extract. A tablet formulation containing fluoride, avicel, and magnesium stearate as components. It is presented. The combined use of these three auxiliary components ensures the desired concentration and consistency. It was found that this made it possible to obtain a tablet formulation of a certain consistency. The inventors specifically mention the species Crataegus pentagyna, Crataegus szovitsii, and Crataegus aronia, Extract of Crataegus curvisepala and Crataegus monogyna species with specific excipients. They discovered that the combined use of fluoride and avicelin was effective. In this way, both The desired tablet specifications can be achieved, and the high yield of the hawthorn extract from the invention is also ensured. Bioavailability and bioaccessibility can be ensured through delivery. Here, Avicel, the components It promotes dry blending, provides compressibility, ideal hardness and low It enables the production of a tablet formulation with a certain degree of crumbling. Florite, on the other hand... It functions as both a stabilizing agent and a carrier. These two auxiliary components work together. Using 35 ingredients results in an ideal tablet formulation. Additionally, the invention relates to Crataegus pentagyna, Crataegus szovitsii, Crataegus aronia, Crataegus Extracts of the species Crataegus curvisepala and Crataegus monogyna, along with specific auxiliary components such as fluoride. Combining Avicel and magnesium stearate results in a powder formulation with stability. by making tablet printing process advantageous in terms of compressibility and dispersibility. It makes things easier. The amount of hawthorn extract in the tablet formulation of the present invention shall preferably be 20% to 20% by weight. It is in the 40% range. Preferably, the amount of hawthorn extract in question is between 100 and 200 mg. More The preferred extract dosage is 115 mg. This amount of extract ensures sufficient metabolites are released into the body. It facilitates the purchase. The ratio of hawthorn extract to fluoride excipient in the tablet formulation of the present invention. The ratio is preferably 1:1 to 1:0.

5. The amount of Avicel, another auxiliary component, is preferably 40% by weight. It is in the range of 55%. Preferably magnesium included in the tablet formulation of the present invention. The stearate content ranges from 0.1% to 1% by weight. The present inventors define this percentage by weight and the quantities minimize tablet dispersibility when the formulation is pressed into tablet form. They discovered that it not only did this, but also provided the required amount of hawthorn extract. For the purposes of this invention, the inventors have used the following species: C. pentagyna, C. szovitsii, C. aronia, C. curvisepala and a tablet formulation of hawthorn extract prepared from C. monogyna species. Presented in this way resulted in significantly higher bioaccessibility values. They have determined that presenting hawthorn extract in tablet form is therapeutically effective. The amount can be easily absorbed by the body. Another aspect of the present invention relates to the preparation of the tablet formulation according to the invention. It provides a method which includes the following steps: - Crataegus pentagyna, Crataegus szovitsii, Crataegus aronia, Crataegus curvisepala and Collecting, drying, and powdering Crataegus monogyna species. - The resulting powder is subjected to ultrasonic extraction using a solvent, - obtaining the extract by subjecting the solution to the lyophilization process, - combining the extract with at least one auxiliary component, - pressing the resulting mixture into tablet form, and - obtaining the final tablet formulation. 35 In the extraction step of the method related to the present invention, the solvent in question is preferred as 45% EtOH. This allows for the extraction of hawthorn varieties from the plant with the highest possible yield. 6 Furthermore, in the aforementioned extraction, the solid / liquid (powder / drug / solvent) ratio of the mixture is preferably 1 / 20. It is determined as follows. The method relating to the present invention preferably involves combining it with at least one auxiliary component. The next step is to combine the extract with fluoride, Avicel, and magnesium stearate. Another aspect of the invention is its potential in the prevention and / or treatment of cardiovascular diseases. A tablet formulation based on the invention is presented for use. With this invention, for the first time, 5 hawthorn species growing in Türkiye are named with their binomial names Crataegus. pentagyna Waldst. & Kit. ex Willd., C. szovitsii Pojark, C. aronia (L.) Bosch. ex DC., C. curvisepala Lindman recorded 36 different sites for C. monogyna Jacq. and analyzed the collected samples. It has been revealed. The tablet formulation containing the extract of specific hawthorn species belonging to the present invention is beneficial to human health. Its contribution is demonstrated by the present invention. In addition to the effects described above, it is particularly noteworthy. the present invention which contributes to the treatment and prevention of cardiovascular diseases The easy availability of hawthorn extract in tablet form, and the metabolites present in the formulation The high quantity and low cost of industrial-scale production make the current invention attractive. Their formulations have advantages compared to currently existing plant-based tablet formulations. It makes it possible. As explained in detail in the Examples below; hawthorn collected within the scope of the present invention In studies conducted with examples, Soxhlet, ultrasonic, microwave and subcritical water were used. Four different extraction methods were tried, including ultrasonic extraction. This method has been determined to be the most suitable method. First, samples from the identified areas. They were collected, dried, and prepared for extraction. Extraction processes After completion, standardization was carried out based on the active ingredient. Regarding the invention... Tablet formulations were developed and prototype tablets were prepared. The data obtained are fundamental. more comprehensive tests and quality controls are carried out on the tablets prepared during the production phase. This process reveals the necessary data for industrial-scale production. EXAMPLES Details regarding the preparation and testing of tablet formulations based on the present invention. 35 are shared below. Technical experts can design within the scope of the attached requirements. They will understand that the structures cannot be limited to those given here. 7 Example 1. Harvesting Hawthorn Species From different geographical regions of Türkiye (Thrace, Western Black Sea, Aegean, Mediterranean, Eastern Anatolia, for extraction from Southeastern Anatolia and from different altitudes (sea level to 2000 m) Leaf + bud and leaf + flower mixed specimens were collected. Herbarium specimens (voucher specimens) representing the species being studied ensure accurate identification of the species. It is very effective in showing that it is unidentified. Therefore, sufficient herbarium material is needed. Care was taken to collect them. Species collection locations: Samples of 5 species were collected from 18 different locations. C. pentagyna; 2 areas: Thrace, Western Black Sea, C. szovitsii; 2 areas: Thrace, Niğde Hasan Da., or Malatya – Elazığ, C. aronia; 3 areas: Muğla, Kayseri, Adıyaman (or Hatay), C. curvisepala; 3 areas: Kastamonu, Malatya, Hakkari C. monogyna; 8 areas: Thrace, Adana (Saimbeyli), Erzincan, Izmir, Mardin, Taurus Mountains (sea level -500 m, 1500-2000 m, north slope) The drug was collected by dividing the flowering and fruiting periods of a tree into stages. These stages were: This is explained below:  Leaf + Flower: The stage when all the flowers have opened.  leaf + young fruit: the stage when the fruits are green In conclusion, a total of 36 different materials were collected from 18 areas. This was used to identify hawthorn species. Mature fruit characteristics (size, color, number of seeds, etc.) are decisive. Example 2. Preparation of Hawthorn Extract Phytochemicals are generally found in plants in low concentrations and are chemically... It is delicate. Therefore, the extraction of useful components from plants and the identification of those components are sensitive. and constitutes an important step in its use. Crataegus species secondary metabolites It is very rich in terms of nutrients. Therefore, the most suitable extraction method should be used. is required. The collected and dried samples are then ground during the period from July to December. The collected and dried plants were subjected to an extraction process. The extracted plants were processed using a TOPER brand KT 17 model machine. It was ground into powder using a mill and prepared for extraction. 35 8 After the field work is completed and the samples are prepared, appropriate extraction methods and Optimization and standardization studies were carried out for the determination of solvents. Ultrasonic The extraction method was found to be the most suitable method for obtaining the extract related to the invention. The ultrasonic wave frequency was set to 20 kHz–1 MH. Five different solvents were used in the extraction. The following were tested: Ethanol (45% and 100%), Methanol, Ethyl acetate, Acetone, and Distilled water. Plant-solvent ratios The ratios were set to 1:5, 1:10, and 1:

20. Extractions were performed over a period of 5 hours. After the extraction was complete, the solvent was removed until the evaporator was dry. The same Extractions were performed in this manner, with 3 repetitions. Ultrasonic extraction is a process used in laboratories. The provided Bandelin Sonorex brand ultrasonic extraction device and Heidolph Hei-VAP-Valve This was achieved using a branded evaporator. In ultrasonic extraction, the most suitable solvent is 45% EtOH, which is the optimal solid / liquid solution. The ratio (powder drug / solvent) was determined to be 1 / 20. Next, samples were prepared for qualitative analysis. HPLC analysis studies were performed on the samples. This was carried out. The hawthorn medicinal plant drug (Crataegi flos cum foliae) contains rutin and hyperoside. By qualitatively and quantitatively determining their amounts using UHPLC, the highest amount of substance is obtained. The species Crataegus monogyna and Crataegus aronia, which possess these characteristics, were identified. The amount of dry sample obtained from the field studies was determined to be 6800 g. The samples... After preparation, it is subjected to lyophilization until it is completely dry and homogenized. It was obtained in the form of dry powder. The total amount of powdered lyophilized samples was measured using a precision balance. It was weighed and found to be 100 g. The powdered extract of the invention, for example, contains 35% Crataegus szovitsii, 30% Crataegus curvisepala, 15% by weight. Crataegus pentagyna may contain 10% Crataegus monogyna and 10% Crataegus aronia. Another For example, 100 g of the powdered extract of the invention, 35 g of Crataegus szovitsii, 30 g of Crataegus curvisepala, 15 g Crataegus pentagyna may contain 10 g of Crataegus monogyna and 10 g of Crataegus aronia. Example 3. Preparation of a Tablet Formulation Containing Hawthorn Extract. The lyophilized hawthorn extract was mixed with the auxiliary components. Then, it was prepared for tablet pressing. Studies were conducted to determine the required powder properties, namely fluidity and compressibility.

35. Improving the hygroscopic (moisture-absorbing) property of the lyophilized powder extract, which has a very high hygroscopic nature. Different adsorbents were used for this purpose. Of these adsorbents, the one with a higher adsorption capacity was chosen. Fluoride was chosen. This was done to ensure the tablet disintegration time was under 15 minutes and also to reduce the powder content. 9 Avicel, another adsorbent, was used in addition to fluorite to improve printing properties. An auxiliary component was added to the formulation. The active ingredient:adsorbent ratio is 1:1 and 1:0.

5. A 0.1% lubricant was used to facilitate the tablet's release from the seal. Magnesium stearate was added. Based on the findings, the extract was prepared in tablet form. Disintegration time was determined to be <5 minutes. Tablets were pressed using 200 psi. The findings are summarized in Table 1 below. The friability of the tablets was <1%. It was detected. Table 1. Characteristics of the obtained tablet formulations. Fluorite Avicel Extract and Weight, Diameter, Thickness, Dispersion Mg Stearate (mg) (mm) (mm) (min) (mg) Avicel: 508.2 15.06 3.66 7.55 230 mg 474.8 15.05 3.55 8.10 514.3 15.06 3.65 7.45 506.2 15.06 3.55 7.50 115 mg 115 mg 475.7 15.05 3.66 8.75 Mg Stearate: 503.2 15.05 3.55 9.00 0.92 mg 480.6 15.05 3.66 9.00 490.4 15.05 3.55 6.90 482.3 15.05 3.66 8.30 477.8 15.06 3.55 8.35 Avicel: 345.7 15.05 2.55 2.07 172.5 mg 344.4 15.05 2.50 3.50 343.1 15.06 2.50 2.50 344.8 15.06 2.50 3.10 115 mg 57.5 mg 343.8 15.05 2.45 4.15 Mg Stearate: 345.7 15.05 2.55 4.50 0.69 mg 345.8 15.06 2.50 3.45 343.6 15.05 2.50 3.75 345.3 15.06 2.55 2.50 344.4 15.06 2.50 2.75 When the values ​​presented for the tablet formulation of the invention in Table 1 are examined... It has been observed that suitable tablet diameter, dispersion, and thickness values ​​have been achieved. The aforementioned Dispersibility values ​​less than 8 minutes for the tablet formulation of the present invention It has been shown to have good dispersibility. The present inventors, thanks to the specific composition of the present invention, can maintain the humidity balance of the environment. By doing this, they prevented the extract from becoming extra soft and sticky. In addition, clumping that might occur when the extract packaging is opened is prevented, thus keeping the powder separate. It has also been shown that there is no flow at all. The scope of protection of the present invention is set out in the attached claims, and this detailed description includes examples. It is obvious that it cannot be limited to what has been described for this purpose. A person who is an expert in the field would know the above. In light of what has been described, and considering the scope of the invention, similar products can be developed. He / She will understand. 11